Paradigm Biopharmaceuticals Ltd
ASX:PAR
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Price:
0.275 AUD
-3.51%
Market Closed
Updated:
May 3, 2024
Paradigm Biopharmaceuticals Ltd
Net Income (Common)
|
Paradigm Biopharmaceuticals Ltd
Net Income (Common) Peer Comparison
Comparables:
IMM
MSB
CSL
CUV
TLX
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
Net Income (Common)
-AU$69m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
|
Immutep Ltd
ASX:IMM
|
Net Income (Common)
-AU$40.5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-12%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Net Income (Common)
-$73.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Net Income (Common)
$2.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Net Income (Common)
AU$30.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Net Income (Common)
AU$5.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Paradigm Biopharmaceuticals Ltd's Net Income (Common)?
Net Income (Common)
-69m
AUD
-69m
AUD
Based on the financial report for Dec 31, 2023, Paradigm Biopharmaceuticals Ltd's Net Income (Common) amounts to -69m AUD.
What is Paradigm Biopharmaceuticals Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-58%
-58%
Over the last year, the Net Income (Common) growth was -56%. The average annual Net Income (Common) growth rates for Paradigm Biopharmaceuticals Ltd have been -35% over the past three years , -58% over the past five years .
You don't have any saved screeners yet
